I would say the "potential" is extremely favorable. It is hard to go wrong delivering proven drug directly to tumor site in an improved manner. I think the company will make some serious money if they have the intellectual rights to keep the process. The next six months depends upon interim results and partnerships. I am not a believer in mathematical odatian crosses as they may or may not apply to a news driven biotech stock. I do believe there will be a run-up as we get closer to results and that there is a real possibility that it could hold/continue if a partnership closely follows. I do respect some of the posters here and the DD that I have observed that they are capable. I personally have some dry powder that I will use to add to my position as we get closer to the end of the "drift" and move into "anticipation" phase.